📊 ISPC Key Takeaways
Is iSpecimen Inc. (ISPC) a Good Investment?
iSpecimen is experiencing severe financial distress with revenue collapsing 79% YoY to just $156K while burning $3.4M in quarterly operating cash. The company faces imminent liquidity crisis with only ~$2.8M cash and less than a quarter's runway at current burn rates, compounded by dangerously high 4.22x debt-to-equity leverage and a current ratio of 0.62x indicating inability to meet short-term obligations.
iSpecimen’s fundamentals are severely impaired, with shrinking revenue, deeply negative operating and net margins, and negative free cash flow that far exceeds its revenue base. Liquidity is weak, leverage is elevated relative to its small equity base, and the current cash position appears insufficient to comfortably support ongoing losses without additional financing or operational improvement.
Why Buy iSpecimen Inc. Stock? ISPC Key Strengths
- Net loss improved 16% YoY (from $2.8M to $2.3M), indicating cost reduction efforts
- Retains $2.8M cash buffer providing minimal runway for operational restructuring
- Operates in specialized biospecimen market with potential recovery if customer base stabilizes
- The company still retains a cash balance of $2.78M, providing some near-term operating flexibility.
- Long-term debt is present but not overwhelmingly large in absolute dollars relative to total assets.
- Diluted EPS improved year over year, indicating losses narrowed somewhat on a per-share basis.
ISPC Stock Risks: iSpecimen Inc. Investment Risks
- Catastrophic revenue decline of 79% YoY signals loss of core customer relationships and market viability
- Liquidity crisis: current ratio 0.62x and quick ratio 0.61x indicate inability to cover current liabilities; negative $3.4M quarterly operating cash flow exhausts remaining cash within months
- Extreme financial leverage at 4.22x debt-to-equity with $3.4M long-term debt against only $814K equity; high covenant breach and restructuring risk
- Negative operating margin of -1627% and negative cash conversion indicates fundamental business model failure
- Zero insider Form 4 activity in 90 days suggests management lacks confidence in company survival
- Revenue declined 6.4% year over year, pointing to weak growth quality and limited operating traction.
- Profitability is extremely poor, with operating margin of -335.1% and net margin of -292.3%.
- Financial health is strained by a 0.63x current ratio, negative operating cash flow, and debt-to-equity of 1.12x.
Key Metrics to Watch
- Cash runway and monthly burn rate (critical indicator of solvency timeline)
- Revenue stabilization and customer concentration metrics (validating business continuity)
- Debt covenant compliance status and refinancing needs (restructuring risk)
- Operating cash flow trend (indicates whether losses are stabilizing or accelerating)
- Revenue growth and evidence of sustained customer demand recovery
- Operating cash burn relative to cash balance and working capital liquidity
iSpecimen Inc. (ISPC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ISPC Profit Margin, ROE & Profitability Analysis
ISPC vs Healthcare Sector: How iSpecimen Inc. Compares
How iSpecimen Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is iSpecimen Inc. Stock Overvalued? ISPC Valuation Analysis 2026
Based on fundamental analysis, iSpecimen Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
iSpecimen Inc. Balance Sheet: ISPC Debt, Cash & Liquidity
ISPC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: iSpecimen Inc.'s revenue has remained relatively flat over the 5-year period, with a 7% decline. The most recent EPS of $-17.58 indicates the company is currently unprofitable.
ISPC Revenue Growth, EPS Growth & YoY Performance
ISPC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $2.7M | -$1.4M | $-2.10 |
| Q2 2024 | $1.6M | -$2.1M | $-0.49 |
| Q1 2024 | $2.3M | -$2.4M | $-0.27 |
| Q3 2023 | $2.6M | -$2.1M | $-0.23 |
| Q2 2023 | $1.6M | -$2.4M | $-0.30 |
| Q1 2023 | $2.5M | -$2.4M | $-0.25 |
| Q3 2022 | $2.6M | -$1.4M | $-0.22 |
| Q2 2022 | $2.3M | -$1.4M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
iSpecimen Inc. Dividends, Buybacks & Capital Allocation
ISPC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for iSpecimen Inc. (CIK: 0001558569)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ISPC
What is the AI rating for ISPC?
iSpecimen Inc. (ISPC) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ISPC's key strengths?
Claude: Net loss improved 16% YoY (from $2.8M to $2.3M), indicating cost reduction efforts. Retains $2.8M cash buffer providing minimal runway for operational restructuring. ChatGPT: The company still retains a cash balance of $2.78M, providing some near-term operating flexibility.. Long-term debt is present but not overwhelmingly large in absolute dollars relative to total assets..
What are the risks of investing in ISPC?
Claude: Catastrophic revenue decline of 79% YoY signals loss of core customer relationships and market viability. Liquidity crisis: current ratio 0.62x and quick ratio 0.61x indicate inability to cover current liabilities; negative $3.4M quarterly operating cash flow exhausts remaining cash within months. ChatGPT: Revenue declined 6.4% year over year, pointing to weak growth quality and limited operating traction.. Profitability is extremely poor, with operating margin of -335.1% and net margin of -292.3%..
What is ISPC's revenue and growth?
iSpecimen Inc. reported revenue of $156.0K.
Does ISPC pay dividends?
iSpecimen Inc. does not currently pay dividends.
Where can I find ISPC SEC filings?
Official SEC filings for iSpecimen Inc. (CIK: 0001558569) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ISPC's EPS?
iSpecimen Inc. has a diluted EPS of $-6.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ISPC a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, iSpecimen Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ISPC stock overvalued or undervalued?
Valuation metrics for ISPC: ROE of -279.5% (sector avg: 15%), net margin of -1,458.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ISPC stock in 2026?
Our dual AI analysis gives iSpecimen Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ISPC's free cash flow?
iSpecimen Inc.'s operating cash flow is $-3.4M, with capital expenditures of $454.0. FCF margin is -2,155.2%.
How does ISPC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,458.4% (avg: 12%), ROE -279.5% (avg: 15%), current ratio 0.62 (avg: 2).
Is iSpecimen Inc. carrying too much debt?
ISPC has a debt-to-equity ratio of 4.22x, which is above the Healthcare sector average of 0.6x. Combined with a current ratio below 1, this warrants careful monitoring of the balance sheet.